Merck KGaA (OTCMKTS:MKGAF) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday, ValuEngine reports.

MKGAF opened at $115.90 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.94 and a debt-to-equity ratio of 0.29. The company has a market cap of $14.98 billion, a price-to-earnings ratio of 20.44 and a beta of 0.69. Merck KGaA has a 52-week low of $96.00 and a 52-week high of $121.40. The firm’s fifty day simple moving average is $117.86 and its two-hundred day simple moving average is $108.73.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: What are high-yield dividend stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.